Literature DB >> 22193518

Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination.

Evanguelos Xylinas1, David R Yates, Raphaële Renard-Penna, Elise Seringe, Jean-Claude Bousquet, Eva Comperat, Marc-Olivier Bitker, Philippe Grenier, Morgan Rouprêt.   

Abstract

OBJECTIVES: To assess the value of dynamic contrast-enhanced magnetic resonance imaging (MRI) for the prediction of extracapsular extension (ECE) in patients with clinical T3 (cT3) prostate cancer (PCa) compared to digital rectal examination (DRE).
MATERIALS AND METHODS: A retrospective review of data for patients treated by radical prostatectomy for cT3 PCa was performed. Patients who underwent MRI in the pre-operative work-up were included. The likelihoods of extracapsular extension (T3a) and seminal vesicle invasion (T3b) were scored on the basis of MR images. For data analysis, receiver operating characteristic (ROC) curves were generated.
RESULTS: Overall, 70 consecutive patients were included. Mean age was 63.8 (range 45-75) years, and the mean PSA level was 11.3 (range 2.9-26) ng/ml. Pathological analysis of the prostatic specimens confirmed 81.4% (n = 57) had pT3 disease. According to MRI, 57 (81.4%) patients were predicted correctly to have T3 disease. The overstaging (actual pT2) by either DRE or MRI or both was 18.6, 7 or 7%, respectively. The sensitivity, specificity and positive (PPV) and negative predictive values (NPV) of MRI were 94.7, 69, 93 and 75%. The kappa index of concordance between pre-operative MRI stage and pathological stage was 0.68 (P < 0.00001). The performance of MRI for T3 staging was AUC 0.87 (95% CI, 0.77-0.97).
CONCLUSIONS: Pre-prostatectomy MRI adds significant incremental value to the assessment of patients with cT3 disease. Its ability to accurately predict and characterize pathological T3 status and its superiority to standard clinical variables (e.g. DRE) confirm its usefulness in pre-operative work-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193518     DOI: 10.1007/s00345-011-0811-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

Review 1.  Prostate cancer: multiparametric MR imaging for detection, localization, and staging.

Authors:  Caroline M A Hoeks; Jelle O Barentsz; Thomas Hambrock; Derya Yakar; Diederik M Somford; Stijn W T P J Heijmink; Tom W J Scheenen; Pieter C Vos; Henkjan Huisman; Inge M van Oort; J Alfred Witjes; Arend Heerschap; Jurgen J Fütterer
Journal:  Radiology       Date:  2011-10       Impact factor: 11.105

2.  Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results.

Authors:  François Cornud; Thierry Flam; Laurent Chauveinc; Khaled Hamida; Yves Chrétien; Annick Vieillefond; Olivier Hélénon; Jean François Moreau
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

3.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

4.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

5.  Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less.

Authors:  T Yamamoto; K Ito; M Ohi; Y Kubota; K Suzuki; Y Fukabori; K Kurokawa; H Yamanaka
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

Review 6.  Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer?

Authors:  Evanguelos Xylinas; Arnaud Daché; Morgan Rouprêt
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

7.  Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997.

Authors:  R O Roberts; E J Bergstralh; M M Lieber; S J Jacobsen
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

8.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Authors:  B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan
Journal:  J Natl Cancer Inst       Date:  1999-06-16       Impact factor: 13.506

9.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

10.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

View more
  5 in total

1.  The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy.

Authors:  Sarah J Drouin; Eva Comperat; Justine Varinot; Christophe Vaessen; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; Pierre Mozer; Shahrokh F Shariat; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-05-31       Impact factor: 4.226

2.  Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadian academic tertiary care centre.

Authors:  Taehyoung Lee; Jen Hoogenes; Ian Wright; Edward D Matsumoto; Bobby Shayegan
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 3.  Innovations in diagnostic imaging of localized prostate cancer.

Authors:  Karl Pummer; Malte Rieken; Herbert Augustin; Thomas Gutschi; Shahrokh F Shariat
Journal:  World J Urol       Date:  2014-08       Impact factor: 4.226

4.  Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL.

Authors:  Charles Dariane; Chloé Le Cossec; Sarah J Drouin; Benoit Wolff; Benjamin Granger; Pierre Mozer; Marc-Olivier Bitker; Shahrokh F Shariat; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-04-26       Impact factor: 4.226

5.  Can high-spatial resolution T2-weighted endorectal MRI rule out clinically significant prostate cancer?

Authors:  Matthias C Roethke; Michaela Kniess; Sascha Kaufmann; Matthias P Lichy; Heinz-Peter Schlemmer; Arnulf Stenzl; David Schilling
Journal:  World J Urol       Date:  2013-06-11       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.